Safety Note Before Choosing Capsules or Shots BPC-157 should not be treated like a basic supplement
NR = not reached At the protocol specified final OS analysis, the median in the pemetrexed in combination with pembrolizumab and platinum chemotherapy arm was 22.0 months (95% CI: 19.5, 24.5) compared to 10.6 months (95% CI: 8.7, 13.6) in the placebo with pemetrexed and platinum chemotherapy arm, with an HR of 0.56 (95% CI: 0.46, 0.69)
Because of our product nature, returns are not accepted
The following elements should be present in the medical record for every Z02.2 encounter
Your nurse reviews your health history, confirms the right drip for your goals, and stays with you for the full session to keep you safe and comfortable
The optimal dosage and frequency are determined through consultation with healthcare professionals, who consider factors such as the underlying cause of deficiency, individual health status, and response to treatment